The check came from an unusual source. When Kivira, a mental health diagnostics startup, closed its $1.8 million pre-seed round, the lead investor wasn't a typical Sand Hill Road firm—it was Wellstar Health System, the Georgia-based operator of 11 hospitals and more than 450 outpatient locations.
Through its Catalyst by Wellstar investment arm, the health system is doing something venture capitalists rarely do: immediately deploying the technology it's funding across its own clinical operations. For Kivira, that means direct access to precisely the environment where its AI-powered diagnostic tools are meant to make the biggest difference—primary care offices, where most Americans first present mental health symptoms but where physicians often lack specialized psychiatric training to sort depression from bipolar disorder, or anxiety from early psychosis.
The University of Chicago and Antler also participated in the round, according to the University of Chicago Booth School of Business and the Polsky Center for Entrepreneurship and Innovation.
When Your Investor Is Also Your Customer
Maria T. Carmona, Kivira's CEO and a three-time founder with Y Combinator backing in her past, framed the Wellstar partnership as validation of a different kind. Strategic capital from a health system operator isn't just money—it's a live laboratory. The arrangement positions Kivira's platform inside real workflows, handling real patients, under the scrutiny of physicians who will use (or ignore) its recommendations based on whether they actually improve outcomes.
It's a high-stakes proving ground, perhaps more demanding than the venture challenge circuit where Kivira took first place and $50,000 at the 18th Annual Global New Venture Challenge at UChicago Booth on June 6, 2025. Academic competitions reward elegant solutions. Health systems demand ones that work under pressure, fit into existing electronic health record systems, and don't slow down clinicians already drowning in administrative tasks.
The Diagnostic Stack
Kivira's approach layers familiar screening instruments—PHQ-9 for depression, GAD-7 for anxiety, C-SSRS for suicide risk—with what the company describes as digital phenotyping and AI models aligned to DSM-5 diagnostic criteria. The system integrates with EHRs and produces what Kivira calls a Clinical Advisory Report, complete with severity bands meant to guide primary care doctors toward more accurate initial assessments.
The platform operates under HIPAA Business Associate Agreements when deployed with provider systems, according to the company's patient app terms. Whether primary care physicians will trust AI-generated diagnostic guidance enough to change their referral patterns remains an open question, one the Wellstar deployment should begin to answer.
Academic Firepower
The company's medical team reads like a who's-who of academic psychiatry. Dr. Teddy Akiki, Clinical Assistant Professor of Psychiatry at Stanford and Co-Director of Stanford's Precision Psychiatry Clinic, serves as Chief Medical Officer. Dr. Charles B. Nemeroff, listed on the Anxiety and Depression Association of America's Board of Directors, holds the Chief Medical Director role. CTO Matthew Vowels brings machine learning expertise from healthcare applications, backed by dual PhDs in Engineering and Applied Mathematics.
That kind of credential density isn't unusual for early-stage health tech. What matters more is whether the technology can deliver results in the messy, time-constrained reality of primary care—where a diagnosis might need to emerge from a 15-minute visit squeezed between a diabetic foot check and a well-child exam.
Validation in Progress
Kivira has indicated plans to pilot its platform with UChicago Medicine and is preparing randomized protocols to compare its diagnostic accuracy against both primary care and behavioral health specialist diagnoses, in collaboration with Stanford's Center for Precision Mental Health. The company has reported completing its medication recommendation model, though the timeline and scope of clinical validation work remains somewhat fluid—as is typical for early-stage health tech companies navigating regulatory and institutional review processes.
The pre-seed capital will fund deployment with Wellstar and support ongoing validation efforts. Headquartered in New York, the company lists a team size between 11 and 50 on LinkedIn, a range broad enough to suggest the workforce is still scaling.
For Wellstar, the bet is straightforward enough: if AI can help primary care doctors catch mental health conditions earlier and route patients more accurately, it could reduce expensive downstream interventions and improve outcomes. For Kivira, the real test begins now—when the technology moves from controlled studies into the chaotic, high-stakes world of everyday clinical practice.
